In vivo findings from male and female mice without diabetes suggest that treatment with SSTR2a and/or SSTR5a may lower blood glucose levels during an OGTT by mechanisms that are partially (via SSTR2a) or entirely (via SSTR5a) dependent on the stimulation of intestinally-derived GLP-1 (Jepsen et al., 2021). The gene discussed is GCG; the disease is diabetes mellitus.